Greg Kennelty

Articles

Expert Sheds Light on Role of Next-Generation Agents in CLL

June 1st 2016

Susan M. O'Brien, MD, discusses upcoming novel treatments in relapsed/refractory chronic lymphocytic leukemia, such as the next generation of inhibition with BTK, SYK, and PI3K, as well as the outcomes of the recent RESONATE-2 trial.

CD4 T-Cell Immunotherapy Has Potential in Multiple Tumor Types

May 29th 2016

Yong-Chen William Lu, PhD, discusses a phase I dose-escalation study investigating the genetically engineered CD4 T cells' ability to target the MAGE-A3 protein.

Role of Radiation Therapy Evolves for Elderly Patients With Breast Cancer

May 23rd 2016

Kevin Hughes, MD, discusses the pros and cons of radiation therapy in elderly patients with breast cancer, as well as luminal A patients, and the overall changing role of the treatment in the field.

Sartor Discusses the Evolving Role of Biomarkers in Prostate Cancer

May 15th 2016

Oliver Sartor, MD, discusses current research with biomarkers in prostate cancer, as well as how some treatments may be utilized as both single agents and in combination.

MRI-US Fusion Targeted Biopsy Better Determines Prostate Cancer Significance, Risk

May 14th 2016

Herbert Lepor, MD, discusses the advent of the MRI-US fusion targeted biopsy and what impact it could have on the field of assessing prostate cancer risk.

Molecular Testing, New Biomarkers on Horizon for Immunotherapy in RCC

May 11th 2016

Mark Ball, MD, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti–PD-1 therapy in renal cell carcinoma, the future of immunotherapy, and what significance genomic testing may hold.

Ribas Shares Emerging Advances With Immunotherapy in Melanoma

May 10th 2016

Antoni Ribas, MD, PhD, shares exciting clinical trial results of immunotherapy agents in patients with melanoma, as well as what the future holds for the field.

Biomarker Leads to New Potential CRC Treatment

April 13th 2016

Deficiency in the protein NOD-like receptor X1 (NLRX1) could represent a potential biomarker to predict response to therapies in patients with colorectal cancer.

Immunotherapy Agents Could Impact All Settings in NSCLC

April 7th 2016

Edward Kim, MD, discusses the impact of nivolumab (Opdivo) and pembrolizumab (Keytruda) in non–small cell lung cancer, potential combinations, biomarkers, and ongoing research.

Immunotherapy Agents Preferred Second Choice in NSCLC, But Questions Remain

April 5th 2016

Sarah Goldberg, MD, MPH, discusses the efficacy of immunotherapies, PD-L1 as a biomarker, and how these therapies will continue to alter the treatment of patients with non–small cell lung cancer.

Lenalidomide Delays Progression in Mantle Cell Lymphoma

March 29th 2016

Lenalidomide (Revlimid) was found to significantly increase progression-free survival in patients with relapsed/refractory mantle cell lymphoma when compared with investigator's choice of single-agent therapy.

Trabectedin Offers Third-Line Option in Uterine Leiomyosarcoma

March 24th 2016

Martee L. Hensley, MD, discusses what lies ahead for the treatment paradigm of uterine leiomyosarcoma

Phase III Studies Aim to Expand Olaparib's Ovarian Cancer Approval

March 22nd 2016

Ursula A. Matulonis, MD, discusses ongoing developments with olaparib, as well as the overall future of PARP inhibitors in ovarian cancer.

Researchers Seek to Optimize PARP Inhibitors in Ovarian Cancer

March 21st 2016

Shannon Westin, MD, discusses refining the use of PARP inhibitors in ovarian cancer by gaining a greater understanding of mechanisms of resistance and exploring combination and sequencing possibilities.

CPX-351 Improves OS in Phase III AML Study

March 15th 2016

Frontline treatment with CPX-351 (Vyxeos) significantly reduced the risk of death by 31% compared with cytarabine and daunorubicin (7+3) for older patients with high-risk, secondary acute myeloid leukemia.

Adjuvant Care at High-Volume Centers Shows Improved Survival in Pancreatic Cancer

March 6th 2016

James L. Abbruzzese, MD, discusses the underlying disparity between high-volume centers and community medical centers affecting patients with pancreatic cancer.

Personalized Therapy Emerging for Patients With Prostate Cancer

March 6th 2016

Tomasz M. Beer, MD, FACP, discusses how having a deeper understanding of the genetic makeup of patients with castration-resistant prostate cancer would open the door to novel treatments, both monotherapy and combination regimens.

Expert Discusses Promise of Immunotherapy in Head and Neck Cancers

February 22nd 2016

Barbara Burtness, MD, discusses the potential for immunotherapy agents in head and neck cancer.

First-in-Class Drug Targets Stem Cells in Gastric Cancer Trial

February 11th 2016

Manish A. Shah, MD, discusses the BRIGHTER trial, which is investigated BBI608 as a second-line treatment for patients with gastric and gastroesophageal junction cancer who already have undergone platinum and fluoropyrimidine-based chemotherapy.

NEXT PAGE
PREVIOUS PAGE